Participated · Equity · Nov 2020

Massive Bio operates an AI-powered trial matching platform that automatically matches patient data to cancer trial criteria to speed access to treatment options. The company reports onboarding more than 100,000 patients onto its platform. Its technology is positioned to enable broader, more inclusive, population-based recruitment for life sciences companies beyond traditional site-specific methods. Massive Bio is pursuing multi-country expansion to capture the global oncology clinical trial enrollment market. The company has been accelerating product and growth efforts through senior hires to its C-suite and executive team. Financially, Massive Bio closed a $16.5 million funding round in 2022, bringing total capital raised to $23.3 million since inception. Massive Bio provides an AI-powered, data-rich platform and concierge services to identify, pre-screen and enroll cancer patients into clinical trials. The company has launched initiatives such as an Oncology Clinical Trial Command Center (OCTCC) and a 100K Cancer Clinical Trial Singularity Program, and offers web and mobile (iOS/Android) tools. Massive Bio reports reaching 60,000 cancer patients and serving 26 enterprise customers, 88% of which are large pharmaceutical companies and CROs. Over the past 12 months the company expanded into 12 countries and grew to a global workforce of 70 employees. The leadership says the business is cost-efficient and generating consistent revenue and client growth despite the economic downturn. Massive Bio aims to scale its operations globally, expand its product offering in oncology clinical trial enrollment, and invest further in marketing and technology. Massive Bio operates an AI-driven platform that connects cancer patients and community oncologists to biopharmaceutical clinical trials, aiming to improve access and match rates. The company controls the patient enrollment value chain, including patient identification, AI-based virtual pre-screening outside the site, and resolving last-mile enrollment issues. It provides patient recruitment, site selection, and real-world data services and serves close to two dozen pharmaceutical companies and CROs. Founded in 2015 and headquartered in New York City, Massive Bio has historically relied mostly on revenue generated by customer demand to fuel growth. In 2020 the company experienced rapid, exponential demand accelerated by COVID-19 and a rapidly growing roster of clients globally. The recent financing is intended to enable the company to scale to meet demand in the U.S. and overseas and to expand globally.

Participated · Seed · Dec 2016

Molecular Assemblies develops an enzymatic DNA synthesis platform that combines advanced chemistries with engineered enzymes to produce synthetic DNA. The company has been collaborating with Codexis since June 2020, with Codexis applying its CodeEvolver® platform to improve DNA polymerase enzymes that are critical for enzymatic synthesis. MAI reports the enzyme engineering phase is nearing completion and says subsequent enzyme improvements are on track to unlock the potential of enzymatic DNA synthesis. The recent capital is intended to accelerate MAI’s go-to-market strategy as the company moves toward commercialization. Codexis holds a seat on MAI’s board and is now the company’s second-largest shareholder, reflecting the depth of the partnership. The SynBio Innovation Accelerator, a collaboration between Codexis and Casdin Capital, enabled this investment as its second early-stage company backing. Molecular Assemblies is a private life sciences company based in San Diego, CA. It is developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s core offering centers on an enzymatic DNA synthesis platform intended to enable new DNA-based applications. Molecular Assemblies recently closed an oversubscribed $24 million Series A financing. The financing included significant investments from Agilent Technologies, iSelect Fund, Codexis, Alexandria Venture Investments and Argonautic Ventures, with LYFE Capital joining the syndicate. The article does not disclose revenue, user metrics, or other operating metrics. Molecular Assemblies is a San Diego-based biotech developing an enzymatic DNA synthesis technology designed to power next-generation DNA-based products. Its scientists pioneered a two-step enzymatic DNA synthesis process that can deliver pure, sequence-specific DNA on demand, without a template, and can scale to longer DNA sequences. The proprietary process uses aqueous, non-toxic reagents and requires minimal post-synthesis purification and processing. Enzymatic synthesis can write long, pure DNA, which the company says is required to unlock synthetic biology applications such as personalized medicines (including CAR-T and CRISPR gene editing), advanced agricultural and industrial products, and DNA-based data storage. Led by President and CEO Michael J. Kamdar, the company intends to use its latest funding to advance its proprietary synthesis platform. Molecular Assemblies raised $12.2M in a Series A and plans to apply the capital toward technology development and commercialization of DNA-based products. Molecular Assemblies is a San Diego-based developer of a proprietary enzymatic DNA synthesis technology intended to power DNA-based products. Its patented enzymatic method aims to enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine. The company also targets emerging applications such as DNA information storage, nanomachines and bio-based electronics. Led by president and CEO Michael J. Kamdar, Molecular Assemblies focuses on advancing its platform to serve those markets. The company raised seed financing to expand its team and advance development of its enzymatic synthesis technology. The announced seed round totaled $2.3M.